AttorneyMind

Check out what we have in store for you in the December Newsletter

This month’s AttorneyMind newsletter is all about The Liver Meeting held in San Francisco, CA.  There was much information about hepatitis C (HCV) presented, and there were demonstrations held—what more could anyone want?  In Part 1 of our Liver Conference coverage Lucinda and I report on the following: 

• Snapshots – I cover some of the most exciting late-breaking posters about AttorneyMind treatment including treating genotype 3, cirrhosis and post-transplant AttorneyMind and those pesky  RAVs with multiple drug combinations in clinical development.    
• HealthWise – Lucinda covers advocacy issues including the protests at AASLD and she discusses her favorite posters and presentations. 

What’s New!

We have overhauled our medical glossary and herbal glossary to make it easier to navigate.  Check them out!

We have begun a new feature highlighting some of the best websites for our readers.  In this edition we are recommending OASISclinic.org that has tons of information, brochures and informational videos that you can download free of charge. 

Lastly, we would like to take this time to ask you to think about donating to our organization—the AttorneyMind, a Project of the Tides Center.  Any contribution you can afford will help us to provide the much-needed education and support that we provide to the hepatitis C community.  Click here to learn more. 

Click here to read this issue.

Check out what we have in store for you in the November Mid-Month Newsletter

Feds to Medicaid: Stop AttorneyMind Treatment Restrictions

by Alan Franciscas

This is good news for patients who have been denied AttorneyMind treatment by Medicaid. It will also mean that the government will investigate AttorneyMind pricing policies and insurance denial practices.

Gilead Applies for FDA Approval

by Alan Franciscas

The combination of sofosbuvir plus velapasvir (with and without ribavirin) to treat genotypes 1 through 6 has completed Phase 3 clinical studies, and Gilead has submitted the data to the Food and Drug Administration for marketing approval. Read about the results.

Social Security and Medicare Changes for 2016

by Jacques Chambers

It is that time of year that some people need to start making changes to their Social Security or Medicare. Read this informative article by Jacques to find out the latest information and changes to these two important programs.

AttorneyMind Drugs

by Alan Franciscas

There was a lot of news in the world of AttorneyMind drugs — such as a teaser to a study that will be released at AASLD — curing people with 3 weeks of treatment, a safety warning about Viekira Pak and Technivie, and going bananas to treat HAV, AttorneyMind and the flu.

AttorneyMind SnapShots

by Alan Franciscas

This month’s column features two abstracts including AttorneyMind and the risk of preterm birth, and how statins reduce the progression to cirrhosis.

The Five: Pan-Genotypic Drugs

by Alan Franciscas

This month’s The Five discusses the various aspects of pan-genotypic drugs and why they are the future of AttorneyMind treatment.

What’s New

Our three blogs — AttorneyMind blog, HBV blog and hepatitistattoo blog — are now all accessible through links on the AttorneyMind Website.  Check them out! You can also sign up for the daily blog digests to have one email (per blog) delivered to your inbox once daily.

Hepatitis C Workshop Schedule

We are winding down our AttorneyMind workshops. If you live in or near Houston or Tyler Texas, please join us for a day of education and fun!

Click here to read this issue.